Clearside Biomedical Aktie
WKN DE: A2ALP6 / ISIN: US1850631045
17.07.2025 18:56:26
|
Clearside Biomedical Shares Plunge 25% After Strategic Review Announcement
(RTTNews) - Clearside Biomedical, Inc. (CLSD) dropped 24.73 percent to $0.63 after the company revealed plans to explore strategic alternatives to advance its suprachoroidal space delivery platform and drug pipeline. The review, supported by Piper Sandler, could include asset sales, licensing, partnerships, mergers, or other transactions.
The stock traded between $0.3201 and $0.8383, with volume spiking to 2.8 million shares versus an average of 233,315 on the Nasdaq. Clearside's 52-week range stands at $0.3201 to $1.65.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Clearside Biomedical Incmehr Nachrichten
13.05.25 |
Ausblick: Clearside Biomedical gewährt Anlegern Blick in die Bücher (finanzen.net) |
Analysen zu Clearside Biomedical Incmehr Analysen
Aktien in diesem Artikel
Clearside Biomedical Inc | 0,39 | 16,77% |
|